Øystein Bruseruds forskningsgruppe

 

2013

 

Cytotherapy. 2013 Apr 24. pii: S1465-3249(13)00409-X. doi: 10.1016/j.jcyt.2013.02.008. [Epub ahead of print] 

Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma.

Mosevoll KA, Akkök CA, Hervig T, Melve GK, Bruserud O, Reikvam H.

 

Cell Death Dis. 2013 Feb 28;4:e516. doi: 10.1038/cddis.2013.39.

Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis.

Gausdal G, Wergeland A, Skavland J, Nguyen E, Pendino F, Rouhee N, McCormack E, Herfindal L, Kleppe R, Havemann U, Schwede F, Bruserud O, Gjertsen BT, Lanotte M, Ségal-Bendirdjian E, Døskeland SO.

 

 

Oncoimmunology. 2013 Feb 1;2(2):e23138. 

Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients.

Sand KE, Rye KP, Mannsåker B, Bruserud O, Kittang AO.

 

 

Toxins (Basel). 2013 Feb 18;5(2):336-62. doi: 10.3390/toxins5020336.

The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine—The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation.

Reikvam H, Fredly H, Kittang AO, Bruserud O.


Mar Drugs. 2013 Jan 30;11(2):332-49. doi: 10.3390/md11020332.

Iodinin (1,6-Dihydroxyphenazine 5,10-Dioxide) from Streptosporangium sp. Induces Apoptosis Selectively in Myeloid Leukemia Cell Lines and Patient Cells.

Myhren LE, Nygaard G, Gausdal G, Sletta H, Teigen K, Degnes KF, Zahlsen K, Brunsvik A, Bruserud O, Døskeland SO, Selheim F, Herfindal L.

 

 

2012

 

Eur Cytokine Netw. 2012 Nov 1;23(4):140-53. doi: 10.1684/ecn.2012.0322.

The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation.

Reikvam H, Hatfield KJ, Fredly H, Nepstad I, Mosevoll KA, Bruserud O.

 

Blood. 2013 Feb 14;121(7):e34-42. doi: 10.1182/blood-2012-05-429555. Epub 2012 Dec 12.

Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.

McCormack E, Mujic M, Osdal T, Bruserud O, Gjertsen BT.

 

Bone Marrow Res. 2012;2012:329061. doi: 10.1155/2012/329061. Epub 2012 Oct 2.

Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress.

Ryningen A, Reikvam H, Nepstad I, Paulsen Rye K, Bruserud O.

 

 

Cancer Chemother Pharmacol. 2012 Oct 6. [Epub ahead of print]

High-dose etoposide in allogeneic stem cell transplantation.

Bruserud O, Reikvam H, Kittang AO, Ahmed AB, Tvedt TH, Sjo M, Hatfield KJ.

 

 

Eur J Haematol. 2012 Oct 9. doi: 10.1111/ejh.12016. [Epub ahead of print]

Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks.

Hatfield KJ, Evensen L, Reikvam H, Lorens JB, Bruserud O.

 

Curr Cancer Drug Targets. 2012 Aug 2. [Epub ahead of print]

Targeted Anti-Leukemic Therapy as Disease-Stabilizing Treatment for Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will It Be Possible To Combine These Strategies with Retransplantation or Donor Lymphocyte Infusions?

Reikvam H, Kittang AO, Melve G, Mosevoll KA, Bentsen PT, Ersvær E, Gjertsen BT, Bruserud O.

 

 

Blood. 2012 Jul 26;120(4):847-57. Epub 2012 Jun 12.

The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.

Lång E, Grudic A, Pankiv S, Bruserud O, Simonsen A, Bjerkvig R, Bjørås M, Bøe SO.

 

 

Expert Opin Investig Drugs. 2012 May;21(5):587-603. Epub 2012 Mar 17.

Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia?

Tsykunova G, Reikvam H, Ahmed AB, Nepstad I, Gjertsen BT, Bruserud O.

 

 

Am J Hematol. 2012 Apr;87(4):368-76. doi: 10.1002/ajh.23116. Epub 2012 Feb 28.

Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.

Fredly H, Reikvam H, Gjertsen BT, Bruserud O.

 

 

Br J Haematol. 2012 Feb;156(4):468-80. doi: 10.1111/j.1365-2141.2011.08960.x. Epub 2011 Dec 13.

Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.

Reikvam H, Hatfield KJ, Ersvaer E, Hovland R, Skavland J, Gjertsen BT, Petersen K, Bruserud O.

 

 

2011

 

Leukemia. 2012 Apr;26(4):563-71. doi: 10.1038/leu.2011.314. Epub 2011 Nov 11.

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.

Reikvam H, Tiu RV.

 

 

Hematology. 2011 Nov;16(6):351-6.

Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia.

Hatfield KJ, Lassalle P, Leiva RA, Lindås R, Wendelboe Ø, Bruserud Ø.

 

 

Bone Marrow Res. 2011;2011:570796. Epub 2010 Oct 4.

Future perspectives: therapeutic targeting of notch signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies.

Ersvaer E, Hatfield KJ, Reikvam H, Bruserud O.                                  

 

 

Biol Blood Marrow Transplant. 2012 Feb;18(2):190-9. Epub 2011 Oct 20.

The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications.

Reikvam H, Mosevoll KA, Melve GK, Günther CC, Sjo M, Bentsen PT, Bruserud Ø.

 

 

J Infect Dis. 2011 Dec;204(11):1779-86. Epub 2011 Oct 11.

Human cellular immune response against Giardia lamblia 5 years after acute giardiasis.

Hanevik K, Kristoffersen E, Svard S, Bruserud O, Ringqvist E, Sørnes S, Langeland N.

 

 

Cancer Immunol Immunother. 2011 Dec;60(12):1669-81. Epub 2011 Oct 12.

Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?

Ersvær E, Melve GK, Bruserud O.

 

 

Expert Rev Hematol. 2011 Oct;4(5):563-76.

The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target?

Melve GK, Ersvssr E, Kittang AO, Bruserud O.

 

 

Cytotherapy. 2011 Nov;13(10):1259-68. doi: 10.3109/14653249.2011.605117. Epub 2011 Sep 12.

Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma.

Akkök CA, Hervig T, Stamnesfet S, Nesthus I, Melve GK, Lassalle P, Bruserud O.

 

 

Leuk Res. 2011 Sep;35(9):1156-8. Epub 2011 Jul 30.

Heat shock protein 90 (HSP90) inhibition in acute myeloid leukemia--targeting of disease heterogeneity through direct and indirect antileukemic effects.

Bruserud Ø, Hatfield KJ, Reikvam H.

 

 

J Biomed Biotechnol. 2011;2011:104631. Epub 2011 May 3.

Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.

Reikvam H, Hatfield KJ, Kittang AO, Hovland R, Bruserud Ø.

 

 

Cytotherapy. 2011 Sep;13(8):1013-24. Epub 2011 Apr 20.

Is there a scientific basis for a recommended standardization of collection and cryopreservation of peripheral blood stem cell grafts?

Akkök CA, Liseth K, Melve GK, Ersvaer E, Hervig T, Bruserud Ø.

 

 

Oncol Rep. 2011 Jun;25(6):1549-56. doi: 10.3892/or.2011.1229. Epub 2011 Mar 22.

Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis.

Fredly H, Ersvær E, Gjertsen BT, Bruserud O.

 

 

Eur Cytokine Netw. 2011 Mar;22(1):52-62.

A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia.

Apelseth TO, Hervig T, Wentzel-Larsen T, Petersen K, Reikvam H, Bruserud Ø.

 

 

Blood Rev. 2011 May;25(3):113-22. Epub 2011 Feb 12.

Current practice and future directions for optimization of platelet transfusions in patients with severe therapy-induced cytopenia.

Apelseth TO, Hervig T, Bruserud O.

 

 

J Proteomics. 2011 Mar 1;74(3):269-81. Epub 2010 Nov 12.

Untangling the intracellular signalling network in cancer--a strategy for data integration in acute myeloid leukaemia.

Jørgensen KM, Hjelle SM, Øye OK, Puntervoll P, Reikvam H, Skavland J, Anderssen E, Bruserud Ø, Gjertsen BT.

 

 

2010

 

Curr Top Microbiol Immunol. 2010;341:v-vi.

The chemokine system in experimental and clinical hematology. Preface.

Bruserud Ø.

 

 

Expert Opin Ther Targets. 2010 Nov;14(11):1139-42.

Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity.

Bruserud Ø, Reikvam H.

 

 

Hematology. 2010 Oct;15(5):338-43.

Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases.

Fredly H, Stapnes Bjørnsen C, Gjertsen BT, Bruserud Ø.

 

 

Blood. 2010 Sep 2;116(9):1389-90.

Antivascular combo therapy: up-and-coming.

Bruserud O, Hatfield K.

 

 

Eur Cytokine Netw. 2010 Sep;21(3):154-64. Epub 2010 Aug 20.

Hypoxia increases HIF-1α expression and constitutive cytokine release by primary human acute myeloid leukaemia cells.

Hatfield KJ, Bedringsaas SL, Ryningen A, Gjertsen BT, Bruserud O.

 

 

Leuk Res. 2010 Nov;34(11):1422-3. Epub 2010 Jul 16.

Heat shock protein 90 (HSP90) inhibition--from experimental to clinical studies.

Bruserud Ø, Reikvam H.

 

 

J Biomed Biotechnol. 2010;2010:692097. Epub 2010 Jun 2.

Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.

Liseth K, Ersvaer E, Hervig T, Bruserud Ø.

 

 

BMC Immunol. 2010 Jul 9;11:38.

Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells.

Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud Ø.

 

 

Genome Med. 2010 Jun 29;2(6):41.

Clinical proteomics of myeloid leukemia.

Hjelle SM, Forthun RB, Haaland I, Reikvam H, Sjøholt G, Bruserud O, Gjertsen BT.

 

 

Nutr Cancer. 2010;62(5):574-83.

Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia.

McCormack E, Skavland J, Mujic M, Bruserud Ø, Gjertsen BT.

 

 

Transfus Apher Sci. 2010 Aug;43(1):33-6. Epub 2010 Jun 16.

Minor diurnal and activity-induced variations in daytime peripheral blood platelet counts do not have any major impact on platelet yield by platelet apheresis.

Akkök CA, Hervig T, Bjørsvik S, Underdal MO, Skoug CF, Ersvaer E, Bruserud Ø.

 

 

Apoptosis. 2010 Aug;15(8):946-55.

Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005).

Hampson P, Wang K, Milverton L, Ersvaer E, Bruserud O, Lord JM.

 

 

Curr Top Microbiol Immunol. 2010;341:149-72.

The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications.

Kittang AO, Hatfield K, Sand K, Reikvam H, Bruserud Ø.

 

 

Curr Top Microbiol Immunol. 2010;341:3-12.

The chemokine system in experimental and clinical hematology.

Bruserud Ø, Kittang AO.

 

 

Eur Cytokine Netw. 2010 Mar;21(1):40-9.

Early pre-engraftment, functional, in vitro responsiveness of T lymphocytes in allotransplanted, acute leukemia patients: proliferation and release of a broad profile of cytokines, possibly predictive of graft-versus-host disease.

Liseth K, Sjo M, Paulsen K, Bruserud Ø, Ersvaer E.

 

 

Expert Opin Investig Drugs. 2010 Feb;19(2):169-83.

Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.

Reikvam H, Hatfield KJ, Lassalle P, Kittang AO, Ersvaer E, Bruserud Ø.

 

 

Toxins (Basel). 2010 Jan;2(1):174-94. Epub 2010 Jan 22.

The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity.

Ersvaer E, Kittang AO, Hampson P, Sand K, Gjertsen BT, Lord JM, Bruserud O.

 

 

Transfusion. 2010 Apr;50(4):766-75. Epub 2009 Dec 18.

Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods.

Apelseth TO, Bruserud O, Wentzel-Larsen T, Hervig T.

 

 

Eur J Haematol. 2010 Mar;84(3):239-51. Epub 2009 Nov 17.

Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.

Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O.

 

 

Biochim Biophys Acta. 2010 Jan;1798(1):1-8. Epub 2009 Oct 31.

Connexin-based signaling in acute myelogenous leukemia (AML).

Foss B, Tronstad KJ, Bruserud Ø.

 

 

2009

 

Crit Rev Oncog. 2009;15(1-2):1-41.

Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia.

Reikvam H, Olsnes AM, Gjertsen BT, Ersvar E, Bruserud Ø.

 

 

Crit Rev Oncog. 2009;15(1):1-36.

Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia.

Reikvam H, Olsnes AM, Gjertsen BT, Ersvar E, Bruserud O.

 

 

Cytotherapy. 2009;11(6):749-60.

Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte- and platelet-derived soluble mediators.

Akkök CA, Liseth K, Hervig T, Ryningen A, Bruserud Ø, Ersvaer E.

 

 

Transfusion. 2009 Aug;49(8):1709-19.

Long-term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells.

Liseth K, Ersvær E, Abrahamsen JF, Nesthus I, Ryningen A, Bruserud Ø.

 

 

Br J Haematol. 2009 Jun;145(6):761-74. Epub 2009 Apr 20.

The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells.

Olsnes AM, Ersvaer E, Ryningen A, Paulsen K, Hampson P, Lord JM, Gjertsen BT, Kristoffersen EK, Bruserud Ø.

 

 

Stem Cells Dev. 2009 Jul-Aug;18(6):807-12.

Connexins are active participants of hematopoietic stem cell regulation.

Foss B, Hervig T, Bruserud O.

 

 

Expert Opin Investig Drugs. 2009 Apr;18(4):433-55.

Targeted therapy in acute myeloid leukaemia: current status and future directions.

Stapnes C, Gjertsen BT, Reikvam H, Bruserud Ø.

 

 

BMC Cancer. 2009 Mar 5;9:77.

Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia.

Øyan AM, Anensen N, Bø TH, Stordrange L, Jonassen I, Bruserud Ø, Kalland KH, Gjertsen BT.

 

 

Tidsskr Nor Laegeforen. 2009 Feb 26;129(5):416-9.

[Granulocyte transfusion]. [Article in Norwegian]

Reikvam H, Blom US, Kristoffersen E, Liseth K, Bruserud O, Hervig T.

 

 

Br J Haematol. 2009 Jan;144(1):53-68. Epub 2008 Oct 30.

Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators.

Hatfield K, Øyan AM, Ersvaer E, Kalland KH, Lassalle P, Gjertsen BT, Bruserud Ø.

 

 

Leuk Res. 2009 Jun;33(6):779-87. Epub 2008 Nov 12.

A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.

Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT, Bruserud O.

 

Transfusion. 2009 Feb;49(2):354-61. Epub 2008 Oct 28.

Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells.

Akkök CA, Holte MR, Tangen JM, Ostenstad B, Bruserud O.

 

 

2008

 

Curr Cancer Drug Targets. 2008 Dec;8(8):666-75.

Anticancer immunotherapy in combination with proapoptotic therapy.

Bruserud Ø, Ersvaer E, Olsnes A, Gjertsen BT.

 

 

Hematology. 2008 Dec;13(6):329-32.

Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors.

Olsnes AM, Ersvaer E, Ryningen A, Bruserud O.

 

 

Expert Opin Investig Drugs. 2008 Nov;17(11):1623-33.

In vivo biological effects of ATRA in the treatment of AML.

Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT, Bruserud O.

 

 

J Interferon Cytokine Res. 2008 May;28(5):297-310.

In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22.

Olsnes AM, Ryningen A, Ersvaer E, Bruserud Ø.

 

 

Transfusion. 2008 May;48(5):877-83. Epub 2008 Feb 21.

Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation.

Akkök CA, Liseth K, Nesthus I, Løkeland T, Tefre K, Bruserud O, Abrahamsen JF.

 

 

Platelets. 2008 Mar;19(2):155-9.

Platelet-released supernatants enhance hematopoietic stem cell proliferation in vitro.

Foss B, Bruserud O, Hervig T.

 

 

Thromb Haemost. 2008 Jan;99(1):27-37.

Platelet functions and clinical effects in acute myelogenous leukemia.

Foss B, Bruserud O.

 

 

Blood. 2008 Mar 1;111(5):2866-77. Epub 2008 Jan 8.

Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death.

Gausdal G, Gjertsen BT, McCormack E, Van Damme P, Hovland R, Krakstad C, Bruserud Ø, Gevaert K, Vandekerckhove J, Døskeland SO.

 

 

 

 

2007

 

Curr Pharm Biotechnol. 2007 Dec;8(6):401-11.

Epigenetic targeting in acute myeloid leukemia: use of flow cytometry in monitoring therapeutic effects.

Ryningen A, Bruserud Ø.

 

 

Curr Pharm Biotechnol. 2007 Dec;8(6):344-54.

Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in acute myeloid leukemia.

Oyan AM, Bø TH, Jonassen I, Ulvestad E, Tore Gjertsen B, Bruserud O, Kalland KH.

 

 

Curr Pharm Biotechnol. 2007 Dec;8(6):318-9.

Introduction: RNA and the treatment of human cancer.

Bruserud O.

 

 

Int J Oncol. 2007 Dec;31(6):1529-38.

Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors.

Stapnes C, Ryningen A, Hatfield K, Øyan AM, Eide GE, Corbascio M, Kalland KH, Gjertsen BT, Bruserud Ø.

 

 

Expert Opin Ther Targets. 2007 Aug;11(8):1055-69.

Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling.

Hagland H, Nikolaisen J, Hodneland LI, Gjertsen BT, Bruserud Ø, Tronstad KJ.

 

 

Eur J Haematol. 2007 Sep;79(3):210-25. Epub 2007 Jul 26.

Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients.

Ersvaer E, Zhang JY, McCormack E, Olsnes A, Anensen N, Tan EM, Gjertsen BT, Bruserud O.

 

 

Hematology. 2007 Jun;12(3):199-207.

Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex.

Ersvaer E, Hampson P, Wendelbo Ø, Lord JM, Gjertsen BT, Bruserud Ø.

 

 

Mol Cancer. 2007 May 11;6:33.

Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.

Wergeland L, Sjøholt G, Haaland I, Hovland R, Bruserud Ø, Gjertsen BT.

 

 

Expert Rev Anticancer Ther. 2007 May;7(5):741-51.

Early gene expression of acute myeloid leukemia in response to chemotherapy.

Anensen N, Øyan AM, Huseby S, Kalland KH, Bruserud Ø, Gjertsen BT.

 

 

Mol Cancer. 2007 Apr 23;6:31.

LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro.

Huang TS, Myklebust LM, Kjarland E, Gjertsen BT, Pendino F, Bruserud Ø, Døskeland SO, Lillehaug JR.

 

 

Anal Biochem. 2007 Jul 1;366(1):46-58. Epub 2007 Mar 18.

Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization.

Petersen K, Oyan AM, Rostad K, Olsen S, Bø TH, Salvesen HB, Gjertsen BT, Bruserud O, Halvorsen OJ, Akslen LA, Steen VM, Jonassen I, Kalland KH.

 

 

Leuk Res. 2007 Sep;31(9):1303-13. Epub 2007 Apr 9.

Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.

Ryningen A, Stapnes C, Bruserud Ø. 

 

 

 

Transfusion. 2007 Apr;47(4):653-65.

In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. 

Apelseth TØ, Bruserud Ø, Wentzel-Larsen T, Bakken AM, Bjørsvik S, Hervig T.

 

 

Br J Haematol. 2007 Mar;136(6):814-28.

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.

Stapnes C, Døskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB, Gjertsen BT, Bruserud O.

 

 

Haematologica. 2007 Mar;92(3):332-41.

Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. 

Bruserud Ø, Ryningen A, Olsnes AM, Stordrange L, Øyan AM, Kalland KH, Gjertsen BT.

 

 

Cancer Immunol Immunother. 2007 Jun;56(6):913-25. Epub 2006 Nov 8.

T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. 

Ersvaer E, Hampson P, Hatfield K, Ulvestad E, Wendelbo Ø, Lord JM, Gjertsen BT, Bruserud Ø.

 

 

Blood. 2007 Mar 15;109(6):2589-96. Epub 2006 Nov 14.

Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. 

Irish JM, Anensen N, Hovland R, Skavland J, Børresen-Dale AL, Bruserud O, Nolan GP, Gjertsen BT.

 

 

Cancer Immunol Immunother. 2007 Jan;56(1):13-24. Epub 2006 Apr 13.

Effects of interferon gamma on native human acute myelogenous leukaemia cells. 

Ersvaer E, Skavland J, Ulvestad E, Gjertsen BT, Bruserud Ø.

 

 

 

 

2006

 

Platelets. 2006 Aug;17(5):296-302.

Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy. 

Ryningen A, Apelseth T, Hausken T, Bruserud Ø.

 

 

Int J Cancer. 2006 Nov 15;119(10):2313-21.

Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. 

Hatfield K, Ryningen A, Corbascio M, Bruserud O.

 

 

Clin Cancer Res. 2006 Jul 1;12(13):3985-92.

A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia.

Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT.

 

 

Transfusion. 2006 May;46(5):800-10.

Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage.

Apelseth TO, Hervig TA, Wentzel-Larsen T, Bruserud O.

 

 

Acta Oncol. 2006;45(3):346-9.

Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia. 

Stapnes C, Ryningen A, Gjertsen BT, Bruserud Ø.

 

 

 Cancer. 2006 Jun 1;106(11):2397-405.

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. 

Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G; Nordic Study Group for Myeloproliferative Disorders.

 

 

BMC Bioinformatics. 2006 Apr 10;7:198.

Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. 

Van Belle W, Anensen N, Haaland I, Bruserud Ø, Høgda KA, Gjertsen BT.

 

 

Leuk Res. 2006 Dec;30(12):1531-40. Epub 2006 Apr 5.

Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90. 

Ryningen A, Ersvaer E, Øyan AM, Kalland KH, Vintermyr OK, Gjertsen BT, Bruserud Ø.

 

 

 Int J Oncol. 2006 May;28(5):1065-80.

cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. 

Øyan AM, Bø TH, Jonassen I, Gjertsen BT, Bruserud Ø, Kalland KH.

 

 

Expert Opin Ther Targets. 2006 Feb;10(1):51-68.

Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. 

Bruserud Ø, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, Gjertsen BT.

 

 

Cancer Immunol Immunother. 2006 Jul;55(7):830-40. Epub 2005 Nov 3.

T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). 

Olsnes AM, Motorin D, Ryningen A, Zaritskey AY, Bruserud Ø.

 

 

Cancer Immunol Immunother. 2006 Feb;55(2):221-8. Epub 2005 Jul 21.

Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia? 

Bruserud Ø, Tronstad KJ, McCormack E, Gjertsen BT.

 

 

Cancer Immunol Immunother. 2006 Feb;55(2):185-7. Epub 2005 Jul 7.

Immunotherapy in chronic lymphocytic leukemia. 

Bruserud Ø, McCormack E, Gjertsen BT.

 

 

 

2005

 

Curr Drug Targets. 2005 Sep;6(6):631-46.

Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. 

Sjøholt G, Anensen N, Wergeland L, Mc Cormack E, Bruserud Ø, Gjertsen BT.

 

 

Curr Cancer Drug Targets. 2005 Jun;5(4):229-48.

Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. 

Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud Ø.

 

 

 J Cancer Res Clin Oncol. 2005 Jun;131(6):377-84. Epub 2005 Mar 18.

In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serum. 

Bruserud O, Tronstad KJ, Berge R.

 

 

Cytometry B Clin Cytom. 2005 Mar;64(1):18-27.

CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles. 

Oyan AM, Bø TH, Jonassen I, Ulvestad E, Gjertsen BT, Kalland KH, Bruserud O.

 

 

Eur J Haematol. 2005 Jan;74(1):24-34.

Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels. 

Glenjen NI, Hatfield K, Bruserud Ø.

 

 

Leuk Res. 2005 Feb;29(2):185-96.

In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. 

Ryningen A, Wergeland L, Glenjen N, Gjertsen BT, Bruserud O.

 

 

 

 

2004

 

 Eur J Haematol. 2004 Nov;73(5):340-50.

Lipoteichoic acid derived from Enterococcus faecalis modulates the functional characteristics of both normal peripheral blood leukocytes and native human acute myelogenous leukemia blasts. 

Bruserud Ø, Wendelbo Ø, Paulsen K.

 

 

 Int J Cancer. 2004 Oct 10;111(6):858-67.

In vitro effects of native human acute myelogenous leukemia blasts on fibroblasts and osteoblasts. 

Glenjen N, Ersvaer E, Ryningen A, Bruserud Ø.

 

 

Cell. 2004 Jul 23;118(2):217-28.

Single cell profiling of potentiated phospho-protein networks in cancer cells. 

Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud Ø, Gjertsen BT, Nolan GP.

 

 

 Cancer Immunol Immunother. 2004 Aug;53(8):740-7. Epub 2004 May 5.

Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia.

Wendelbo Ø, Nesthus I, Sjo M, Paulsen K, Ernst P, Bruserud Ø.

 

 

Transfusion. 2004 May;44(5):785-9.

Better preservation of early hematopoietic progenitor cells when human peripheral blood progenitor cells are cryopreserved with 5 percent dimethylsulfoxide instead of 10 percent dimethylsulfoxide.

Abrahamsen JF, Rusten L, Bakken AM, Bruserud Ø.

 

 

Haematologica. 2004 Apr;89(4):391-402.

Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. 

Bruserud Ø, Ryningen A, Wergeland L, Glenjen NI, Gjertsen BT.

 

 

Cancer Immunol Immunother. 2004 Aug;53(8):677-80. Epub 2004 Apr 7.

How should clinical data be included in experimental studies of cancer immunology? 

Gjertsen BT, Bruserud Ø.

 

 

Leuk Res. 2004 May;28(5):461-8.

Cellular immune responses in multiple myeloma patients with treatment-induced cytopenia early after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. 

Wendelbo Ø, Nesthus I, Sjo M, Ernst P, Bruserud Ø.